Cytokines (IL-17, IL-23 and IL-33) in Adult Patients with Systemic Lupus Erythematosus in Trinidad and Tobago
Journal of Advances in Medicine and Medical Research,
Page 407-413
DOI:
10.9734/jammr/2022/v34i2031510
Abstract
Systemic lupus erythematosus (SLE) is the most common autoimmune disease. It is characterized by the presence of hundreds of autoantibodies against many organs and tissues, including the presence of a large number of autoantibodies, which are specific to self-antigens mainly of nuclear origin such as Smith antigen, double-stranded DNA (dsDNA), anti-Sjögren’s syndrome-related antigen A and B (SSA/Ro and SSB/La, respectively) and ribonucleoproteins, which are the hallmarks of the disease. Type I and II interferons, interleukin-6 (IL-6), IL-1, tumor necrosis factor-alpha (TNF-α), and immunomodulatory cytokines such as IL-10 and TGF-β are essential players in SLE. Additionally, T-cell-derived cytokines such as IL-17, IL-21, and IL-2 are dysregulated in SLE. In this study among cohorts of 60 individuals attending the hospital clinics in Trinidad and Tobago, blood samples were analyzed and the levels of the essential cytokines were measured using SLE Disease Activity Index (SLEDAI) 2000 score. The results confirmed that serum IL-17 and IL-23 levels were positively correlated with the SLE Disease Activity Index (SLEDAI) 2000 score in these patients. These findings have diagnostic and therapeutic implications. However, more work must be done targeting other cytokines relevant to autoimmunity and SLE in particular. Interleulin-33 is not an SLE marker, as has been noted in other populations.
Keywords:
- Systemic lupus erythematosus
- autoimmune disease
- cytokines
- therapeutic implications
How to Cite
References
Fabien B, Northcott M, Hoi A, Mackay F, Morand E. Clinical associations of serum IL-17 in systemic lupus erythematosus. Arthritis Research & Therapy. 2013;15:R97.
Mok MY, Wu HJ, Lo Y, Lau CS. The relation of IL-17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. J Rheumatol. 2010;37:2046-52.
Yang Z, Liang Y, Xi W, Li C, Zhong R. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin Exp Med. 2011;11:75-80.
Nobee A, Justiz-Vaillant A, Akpaka PE, Poon-King P. Levels of Interleukin 17 and 23 in Patients with Systemic Lupus Erythematosus (SLE) in Trinidad and Tobago. Immunochem Immunopathol. 2016;2:115.
DOI: 10.4172/2469- 9756.1000115
Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288-91. PMID: 11838846.
Justiz-Vaillant AA, Ferrer-Cosme B, Ramirez-Hernandez N. A Female with Systemic Lupus Erythematosus and Streptococcal Pneumonia treated with Intravenous Immunoglobulins (Ivig). Preprint.org 2020,
DOI: 10.20944/preprints202009.0544.v1
Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006;116:1218-22.
Mok MY, Huang FP, Ip WK, Lo Y, Wong FY, Chan EY, Lam KF, Xu D. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 2010;49:520-7.
Pons-Estel G; Alarcon, Graciela S; Scofield, Lacie; Cooper, Glinda S. Understanding the epidemiology and progression of systemic lupus Erythematosus. Seminars in Arthritis and Rheumatism. 2010;39:257–68.
Izati AF, Mohd Shukri ND, Wan Ghazali WS, Che Hussin CM, Wong KK. Increased IL-23R+ Th cells population exhibits higher SLEDAI-2K scores in systemic lupus erythematosus patients. Front Immunol. 2021;12:690908.
Published 2021 Aug 17.
DOI:10.3389/fimmu.2021.690908
Dai H, He F, Tsokos GC, Kyttaris VC. IL-23 limits the production of IL-2 and promotes autoimmunity in lupus. J Immunol. 2017 Aug 1;199(3):903- 910.
DOI: 10.4049/jimmunol.1700418.
-
Abstract View: 38 times
PDF Download: 17 times